Roche (ROG: SIX) group member Genentech has revealed positive top-line results from the Phase II LADDER study of its investigational Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD).
The PDS system is a small, refillable eye implant designed to allow people with wet AMD to go several months without needing to visit the doctor.
Most PDS patients enrolled in the LADDER trial went six months or longer between implant of the device and the first required refill.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze